Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database.
Pål MøllerToni SeppäläInge BernsteinElke Holinski-FederPaola SalaD Gareth EvansAnnika LindblomFinlay MacraeIgnacio BlancoRolf SijmonsJacqueline JeffriesHans VasenJohn BurnSigve NakkenEivind HovigEinar Andreas RødlandKukatharmini TharmaratnamWouter H de Vos Tot Nederveen CappelJames HillJuul WijnenMark JenkinsKate GreenFiona LallooLone SundeMiriam MintsLucio BertarioMarta PinedaMatilde NavarroMonika MorakLaura Renkonen-SinisaloIan M FraylingJohn-Paul PlazzerKirsi PylvanainenMaurizio GenuardiJukka-Pekka MecklinGabriela MösleinJulian R SampsonGabriel Capellanull nullPublished in: Gut (2016)
Relative incidence of subsequent cancer compared with incidence of first cancer was slightly but insignificantly higher than cancer incidence in patients with LS without previous cancer (range 0.94-1.49). The favourable survival after subsequent cancers validated continued follow-up to prevent death from cancer. The interactive website http://lscarisk.org was expanded to calculate the risks by gender, genetic variant and age for subsequent cancer for any patient with LS with previous cancer.